Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Coadministration of Teneligliptin and Empagliflozin High in Healthy Volunteers

NCT07102719 is registered in ClinicalTrials.gov with Handok Inc. as lead sponsor.

NCT NCT07102719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07102719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Crossover, Phase 1 Study to Evaluate Pharmacokinetics and Safety of HD-P023 in Comparison With Coadministration of Teneligliptin and Empagliflozin High in Healthy Volunteers
Lead sponsor
Handok Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 10, 2025
Completion date
October 20, 2025
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers